GlassScriptPhysician profile
Amy R Ruschulte
NPI 1700848496
$2,197.09
in general payments reported to CMS, 2019-2025
28 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $113 · 2021: $195 · 2022: $357 · 2023: $438 · 2024: $499 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.24 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.39 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Abbott Laboratories | $289.39 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $287.78 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $177.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $156.74 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $131.50 | 2019-2025 | |
| Exact Sciences Corporation | $72.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Currax Pharmaceuticals LLC | $63.48 | 2020-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.70 | 2019-2023 | Jardiance |
| Amgen INC. | $54.56 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $53.42 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $52.88 | 2021-2022 | |
| Pulmonx Corporation | $43.77 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.45 | 2025 | Xifaxan |
| Sanofi Pasteur INC. | $30.46 | 2019-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $27.98 | 2025 | |
| Lundbeck LLC | $24.65 | 2024 | Vyepti |
| Ironshore Pharmaceuticals INC. | $22.50 | 2019 | |
| Amarin Pharma, INC. | $21.75 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.25 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.75 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $17.34 | 2025 | Rexulti |
| Daiichi Sankyo INC. | $16.67 | 2025 | Injectafer |
| Mylan Specialty L.P. | $14.72 | 2024 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $13.72 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.52 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ruschulte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.